Validity of models for predicting BRCA1 and BRCA2 mutations (scientific article published on October 2007)

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

Q24531993

Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA)

Q24802704

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2

Q28212276

BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history

Q28267644

A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families

Q28384206

The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews

Q28387376

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium

Q29619206

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews

Q29619407

Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification

Q30759423

Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma

Q33197133

BayesMendel: an R environment for Mendelian risk prediction

Q33241509

Optimal selection of individuals for BRCA mutation testing: a comparison of available methods

Q33993208

Tech.sight. Genetic testing--present and future

Q34049724

High-throughput methods for detection of genetic variation

Q34171894

Evaluating the yield of medical tests

Q34277948

Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2

Q34384153

Understanding mathematical models for breast cancer risk assessment and counseling

Q34419051

BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families

Q34480647

Application of breast cancer risk prediction models in clinical practice

Q35066324

American Society of Clinical Oncology Policy Statement Update: Genetic Testing for Cancer Susceptibility

Q35105968

Genetic analysis of breast cancer in the cancer and steroid hormone study

Q35196511

Screening for 185delAG in the Ashkenazim

Q35238470

Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics

Q35443103

A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO

Q35445946

Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis

Q35603145

Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors

Q35986971

Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force

Q36250215

A General Model for the Genetic Analysis of Pedigree Data

Q36546209

The BOADICEA model of genetic susceptibility to breast and ovarian cancer

Q36695832

Quantitating familial cancer risk: a resource for clinical oncologists

Q40677864

Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations

Q40718941

Genetic epidemiology of breast and ovarian cancers

Q41635656

Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer

Q41745402

Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations

Q43073772

Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals

Q46796026

A breast cancer prediction model incorporating familial and personal risk factors.

Q52000310

Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.

Q52274948

BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing.

Q52897865

Assessing BRCA carrier probabilities in extended families.

Q52997805

Active recruitment increased enrollment in a hereditary cancer registry.

Q53630462

BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes

Q57309394

Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic

Q57903135

Prevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women With Breast Cancer

Q59238528

Age at onset as an indicator of familial risk of breast cancer

Q68512337

Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction

Q72752023

A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center

Q73184242

BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer

Q73328358

Risk models for familial ovarian and breast cancer

Q73371929

Testing for hereditary breast and ovarian cancer in the southeastern United States

Q73682762

Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO

Q74239116

Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2

Q74593466

Pre-counseling education materials for BRCA testing: does tailoring make a difference?

Q74741436

Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk

Q74784103

Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample

Q77476124

A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC

Q78237713

Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry

Q81370600

BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model

Q81415321

Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software

Q81481436

P433

issue

P407

language of work or name

English

Q1860

P1104

number of pages

P304

page(s)

441-450

P577

publication date

2007-10-01

P1433

published in

Annals of Internal Medicine

Q564416

P1476

title

Validity of models for predicting BRCA1 and BRCA2 mutations

P478

volume

147

Reverse relations

cites work (P2860)

Q49905350	A comparison of cancer risk assessment and testing outcomes in patients from underserved vs. tertiary care settings.
Q36547135	A two-stage approach to genetic risk assessment in primary care
Q44171056	Accuracy of BRCA1/2 mutation prediction models in Korean breast cancer patients
Q44211368	Apparently "BRCA-related" breast and ovarian cancer patient with germline TP53 mutation
Q36853664	Assessing biases of information contained in pedigrees for the classification of BRCA-genetic variants: a study arising from the ENIGMA analytical working group
Q51439738	Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO.
Q37739036	Assessing women at high risk of breast cancer: a review of risk assessment models
Q54996542	Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families
Q40350775	BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
Q37407985	BRCA1/2 mutations and triple negative breast cancers
Q39263736	Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications.
Q52672618	Clinicians' use of breast cancer risk assessment tools according to their perceived importance of breast cancer risk factors: an international survey.
Q51280306	Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.
Q33493584	Development and validation of a simple questionnaire for the identification of hereditary breast cancer in primary care
Q36983389	Establishing a program for individuals at high risk for breast cancer
Q34185689	Five-Year and Lifetime Risk of Breast Cancer among U.S. Subpopulations: Implications for Magnetic Resonance Imaging Screening
Q37658464	Frailty Models for Familial Risk with Application to Breast Cancer
Q64104911	Functional analysis of BARD1 missense variants in homology-directed repair and damage sensitivity
Q41706101	Hereditary gynaecologic cancers in Nepal: a proposed model of care to serve high risk populations in developing countries
Q37815309	Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?
Q34727284	Morphological predictors of BRCA1 germline mutations in young women with breast cancer.
Q36926475	Multiple diseases in carrier probability estimation: accounting for surviving all cancers other than breast and ovary in BRCAPRO.
Q34023647	Pathogenesis, prevention, diagnosis and treatment of breast cancer
Q37121713	Performance of BRCA1/2 mutation prediction models in Asian Americans
Q38739022	Performance of BRCA1/2 mutation prediction models in male breast cancer patients.
Q37252756	Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry
Q96163551	Practical implementation of frailty models in Mendelian risk prediction
Q37155632	Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States
Q38658383	Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer.
Q99241072	Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer - Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?
Q28390064	Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk
Q34781646	Providing access to risk prediction tools via the HL7 XML-formatted risk web service.
Q33992404	Recent BRCAPRO upgrades significantly improve calibration
Q34622294	SGO White Paper on ovarian cancer: etiology, screening and surveillance
Q36975906	Simplifying clinical use of the genetic risk prediction model BRCAPRO.
Q47436259	Simpson's paradox in the integrated discrimination improvement
Q39197775	Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated?
Q34329243	The BRCAPRO 5.0 model is a useful tool in genetic counseling and clinical management of male breast cancer cases
Q37767615	The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers
Q34263162	Translational advances regarding hereditary breast cancer syndromes
Q36925152	Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study
Q37599604	Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations

P356	DOI	10.7326/0003-4819-147-7-200710020-00002
P932	PMC publication ID	2423214
P698	PubMed publication ID	17909205